Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 6392Neoplasms 408Ovarian Neoplasms 308Triple Negative Breast Neoplasms 286Prostatic Neoplasms 280Lung Neoplasms 271Colorectal Neoplasms 255Neoplasm Metastasis 254Carcinoma, Non-Small-Cell Lung 221Breast Neoplasms, Male 201Colonic Neoplasms 168Motor Activity 166Pancreatic Neoplasms 164Melanoma 157Carcinoma, Intraductal, Noninfiltrating 139Stomach Neoplasms 128Uterine Cervical Neoplasms 127Head and Neck Neoplasms 124Fatigue 104Breast Carcinoma In Situ 103Carcinoma, Ovarian Epithelial 98Endometrial Neoplasms 96Lymphedema 95Carcinoma, Renal Cell 94Urinary Bladder Neoplasms 93Pain 90Sarcoma 89Small Cell Lung Carcinoma 85Lymphoma 83Esophageal Neoplasms 81

Interventions

saracatinib 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Choriocarcinoma × Breast × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡